BDBM575488 (3R,3'R)-3,3'-((((((2,2'-dimethyl-[1,1'-biphenyl]- 3,3'-diyl)bis(azanediyl))bis(carbonyl))bis(4- methoxypyridine-6,3-diyl))bis(methylene))bis (azanediyl)bis(4-hydroxybutanoic acid)::US11459339, Example 75

SMILES COc1cc(ncc1CN[C@@H](CO)CC(O)=O)C(=O)Nc1cccc(c1C)-c1cccc(NC(=O)c2cc(OC)c(CN[C@@H](CO)CC(O)=O)cn2)c1C

InChI Key InChIKey=PUZDHGPXDVDYGF-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 575488   

TargetProgrammed cell death 1 ligand/protein 1(Human)
Abbisko Therapeutics

US Patent
LigandPNGBDBM575488(US11459339, Example 75 | (3R,3'R)-3,3'-((((((2,2'-...)
Affinity DataIC50: 0.360nMAssay Description:The effect of compounds and positive compounds of the examples of the present invention on the interaction between PD-1 and PD-L1 was determined by t...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/7/2022
Entry Details
US Patent